Raymond James Reiterates Outperform Rating on Monopar Therapeutics (MNPR) following Q4 results

March 27, 2026 4:30 PM

Raymond James analyst Chris Raymond reiterated an Outperform rating and $123.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found